Effect of raloxifene on serum triglycerides in women with a history of hypertriglyceridemia while on oral estrogen therapy
Effect of raloxifene on serum triglycerides in women with a history of hypertriglyceridemia while on oral estrogen therapy
复制标题
DOI：
10.2337/diacare.28.7.1555
复制
发表时间：
2005-07-01
期刊：
影响因子：
16.2
通讯作者：
Anderson, PW
中科院分区：
文献类型：
--
作者：
Carr, MC;Knopp, RH;Anderson, PW
目的：盐酸雷洛昔芬是一种选择性雌激素受体调节剂，迄今为止尚未发现其在正常、糖尿病或高雌二醇血症女性中引起高雌二醇血症。这项研究的目的是评估雷洛昔芬对血清甘油三酯的影响，绝经后妇女谁有增加高血脂症的历史与口服雌激素terapy.Research设计和方法-这是一个单中心，不受控制的，开放标签的研究调查的影响，8周雷洛昔芬（60毫克/天）治疗对血脂。研究对象为12名绝经后妇女，年龄49-73岁，有口服雌激素诱导的高雌二醇血症病史结果：在研究的第2周，3名（25%）受试者因出现明显的高甘油三酯血症而退出试验（>= 11.3 mmol/l [>= 1，000 mg/dl]）。这三名女性的基线甘油三酯和葡萄糖水平较高，没有接受降脂药物治疗，并且比其他研究对象更容易患糖尿病。其余9例患者（75%）完成了8周试验，平均甘油三酯水平从基线至终点无显著性升高。雷洛昔芬治疗还导致肝脂肪酶活性显著降低16%，HDL 2水平升高26%（P = 0.013和0.03，分别）。结论：既往有口服雌激素治疗的高甘油三酯血症史的患者在开始雷洛昔芬治疗后应密切监测血清甘油三酯水平，甚至在开始雷洛昔芬治疗前可能需要补充治疗。
OBJECTIVE -Raloxifene hydrochloride is a selective estrogen receptor modulator that to date has not been shown to cause hypertriglyceridemia in normal, diabetic, or hypertriglyceridemic women. This study was designed to assess the effect of raloxifene on serum triglycerides in postmenopausal women who have a history of increased hypertriglyceridemia with oral estrogen terapy.RESEARCH DESIGN AND METHODS - This was a single-center, uncontrolled, open-label study investigating the effects of 8 weeks of raloxifene (60 mg/day) therapy on plasma lipids. The study subjects were 12 postmenopausal women, ages 49-73 years, with a documented history, of oral estrogen-induced hypertriglyceridemia (serum triglycerides >= 3.39 mmol/l [>= 300 mg/dl]).RESULTS - At week 2 of the study, three (25%) of the subjects withdrew from the trial because they developed marked hypertriglyceridemia (>= 11.3 mmol/l [>= 1,000 mg/dl]) during raloxifene therapy. These three women had higher baseline triglyceride and glucose levels, were not being treated with lipid-lowering agents, and were more likely to have diabetes than the other study subjects. The remaining nine patients (75%) completed the 8-week trial and experienced a nonsignificant increase in mean triglyceride levels from baseline to end point. Raloxifene treatment also resulted in a significant 16% decrease in hepatic lipase activity and a 26% increase in HDL2 levels (P = 0.013 and 0.03, respectively).CONCLUSIONS - Patients with a previous history of hypertriglyceridemia on oral estrogen therapy should have serum triglyceride levels monitored closely after beginning raloxifene therapy and may even require fibratc therapy before beginning raloxifene.